跳到正文
心血管健康证据综述4 分钟阅读

降压可减少新发2型糖尿病,但不同降压药效果不同

MoveVitals 编辑部 · 研究发表 · 解读更新

原文:Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. · Lancet (London, England) · 2021 · 论文原文 ↗

先看重点

在19项随机试验、145 939名参与者中,收缩压每降低5 mm Hg,新发2型糖尿病风险降低11%(风险比0.89,95%置信区间0.84-0.95),但各类药物效果不同:ACE抑制剂和ARB降低风险,β受体阻滞剂和噻嗪类利尿剂升高风险。这些试验开展于1973年至2008年,并非专为预防糖尿病而设计,糖尿病不是原先的主要终点。

证据类型

证据综述

解读依据

公开摘要

阅读重点

方法与适用范围

研究在问什么

已知降压可预防糖尿病患者的并发症,但能否预防糖尿病本身尚不清楚。作者利用大型随机试验的个体参与者数据,检验了降低血压本身以及五类主要降压药对新发2型糖尿病的不同影响。

研究了谁,如何研究

由降压治疗试验者协作组(Blood Pressure Lowering Treatment Trialists' Collaboration)开展个体参与者数据荟萃分析,纳入1973年至2008年的22项研究。试验须将某类药物与安慰剂或其他类药物比较,且每个分组至少有1000人年随访;基线已有糖尿病者被排除。单阶段荟萃分析(19项试验)用分层Cox模型评估降压本身的效果,网络荟萃分析(22项试验)用逻辑回归比较药物类别。随访中位数为4.5年(四分位距2.0)。

主要发现

以下为作者报告的结果。数字须连同人群和不确定性一起阅读。

  1. 1
    145 939名参与者(男性88 500人,女性57 429人)中,9883人被诊断为新发2型糖尿病。
  2. 2
    收缩压降低5 mm Hg,2型糖尿病风险降低11%(风险比0.89,95%置信区间0.84-0.95)。
  3. 3
    与安慰剂相比,血管紧张素转换酶抑制剂(相对危险度0.84,95%置信区间0.76-0.93)和血管紧张素II受体阻滞剂(相对危险度0.84,95%置信区间0.76-0.92)降低了风险。
  4. 4
    β受体阻滞剂(相对危险度1.48,95%置信区间1.27-1.72)和噻嗪类利尿剂(相对危险度1.20,95%置信区间1.07-1.35)升高了风险,钙通道阻滞剂无明显影响(相对危险度1.02,95%置信区间0.92-1.13)。

局限与不确定性

  1. 1
    试验开展于1973年至2008年,随访中位数仅4.5年,当前临床实践和长期效果可能不同。
  2. 2
    纳入的是高血压或有心血管风险的人群,基线有糖尿病者被排除,结果不适用于血压正常的人。
  3. 3
    药物类别比较来自网络荟萃分析,摘要未报告各试验如何判定新发糖尿病。
  4. 4
    作者将药物差异归因于脱靶效应,但本分析并未检验这一点。本解读仅基于摘要。

对日常健康的启示

对需要降压治疗的人来说,药物选择可能影响日后的糖尿病风险,本研究中ACE抑制剂和ARB的结果最有利,但β受体阻滞剂和噻嗪类利尿剂仍因充分的理由被使用。不要因为这一发现自行停药或换药,降压治疗的决定应由你的临床医生做出。

如何联系自己的数据

家用血压计在每天相同时间、相同体位测量,可以让你和医生看到血压水平是否在变化,这正是本研究所关注的暴露。体重和空腹血糖记录可为糖尿病风险提供背景,数周的趋势比单次读数更重要。

如何理解这类证据

先看纳入了哪些设计、检索与偏倚评估如何完成,以及检索截止日期;发表新不代表底层证据都是最新的。

作者的结构化摘要 English

以下英文摘要按记录的开放许可转载,属于作者原始材料,不是 MoveVitals 的解读。上方已提供研究解读,分别说明作者结果与本站解释;重要结论可直接核对原文。

Background

Blood pressure lowering is an established strategy for preventing microvascular and macrovascular complications of diabetes, but its role in the prevention of diabetes itself is unclear. We aimed to examine this question using individual participant data from major randomised controlled trials.

Methods

We performed a one-stage individual participant data meta-analysis, in which data were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset type 2 diabetes. An individual participant data network meta-analysis was used to investigate the differential effects of five major classes of antihypertensive drugs on the risk of new-onset type 2 diabetes. Overall, data from 22 studies conducted between 1973 and 2008, were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We included all primary and secondary prevention trials that used a specific class or classes of antihypertensive drugs versus placebo or other classes of blood pressure lowering medications that had at least 1000 persons-years of follow-up in each randomly allocated arm. Participants with a known diagnosis of diabetes at baseline and trials conducted in patients with prevalent diabetes were excluded. For the one-stage individual participant data meta-analysis we used stratified Cox proportional hazards model and for the individual participant data network meta-analysis we used logistic regression models to calculate the relative risk (RR) for drug class comparisons.

Findings

145 939 participants (88 500 [60·6%] men and 57 429 [39·4%] women) from 19 randomised controlled trials were included in the one-stage individual participant data meta-analysis. 22 trials were included in the individual participant data network meta-analysis. After a median follow-up of 4·5 years (IQR 2·0), 9883 participants were diagnosed with new-onset type 2 diabetes. Systolic blood pressure reduction by 5 mm Hg reduced the risk of type 2 diabetes across all trials by 11% (hazard ratio 0·89 [95% CI 0·84-0·95]). Investigation of the effects of five major classes of antihypertensive drugs showed that in comparison to placebo, angiotensin-converting enzyme inhibitors (RR 0·84 [95% 0·76-0·93]) and angiotensin II receptor blockers (RR 0·84 [0·76-0·92]) reduced the risk of new-onset type 2 diabetes; however, the use of β blockers (RR 1·48 [1·27-1·72]) and thiazide diuretics (RR 1·20 [1·07-1·35]) increased this risk, and no material effect was found for calcium channel blockers (RR 1·02 [0·92-1·13]).

Interpretation

Blood pressure lowering is an effective strategy for the prevention of new-onset type 2 diabetes. Established pharmacological interventions, however, have qualitatively and quantitively different effects on diabetes, likely due to their differing off-target effects, with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers having the most favourable outcomes. This evidence supports the indication for selected classes of antihypertensive drugs for the prevention of diabetes, which could further refine the selection of drug choice according to an individual's clinical risk of diabetes.

Funding

British Heart Foundation, National Institute for Health Research, and Oxford Martin School.

来源与署名

Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.

Nazarzadeh M, Bidel Z, Canoy D, Copland E, Wamil M, Majert J, Smith Byrne K, Sundström J, Teo K, Davis BR, Chalmers J, Pepine CJ, Dehghan A, Bennett DA, Smith GD, Rahimi K, Blood Pressure Lowering Treatment Trialists’ Collaboration.

Lancet (London, England) · 2021-11-01

DOI: 10.1016/s0140-6736(21)01920-6 ↗PubMed · 34774144 ↗Europe PMC · 记录的开放许可: cc by ↗

摘要版权归原作者,依据来源记录的开放许可转载。中文译文辅助阅读,英文摘要用于核对术语与具体数值;本站的方法学解释与作者结论分别呈现。

MoveVitals 编辑解读 · 健康教育内容 · 未记录个人临床审阅

来源核验日期 2026-11-01

实用健康指南

放在一起读

·观察研究荟萃分析

昼夜活动节律紊乱与更高的死亡风险相关(109,365人)

在7项观察性研究、共109,365名参与者中,昼夜活动对比较弱(相对振幅较低)与更高的心血管死亡风险(风险比[HR]1.50,95%置信区间1.13至1.98)和全因死亡风险(HR 1.46,95%置信区间1.27至1.68)相关。证据基础小,又是观察性的,不能说明改善节律就能降低风险,疾病本身也可能扰乱节律。

Journal of the American Heart Association

重点论文精讲阅读论文 →
·随机试验荟萃分析

五类运动都降低了静息血压,等长训练降幅最大

汇总270项随机试验、共15,827名参与者的结果,有氧、抗阻、联合、间歇和等长训练与无干预对照组相比都降低了静息血压(各P<0.001),其中等长训练降幅最大:收缩压下降8.24 mm Hg,舒张压下降4.00 mm Hg。各方式之间的排序部分来自间接比较,各试验也不尽相同,所以排序不是个人的运动处方。

British Journal of Sports Medicine

重点论文精讲阅读论文 →
·随机对照试验

盐替代品使中国农村高危人群的卒中、主要心血管事件和死亡率下降

在中国农村600个村庄、20,995名有卒中史或年龄在60岁及以上且有高血压的人中,使用盐替代品(氯化钠75%、氯化钾25%)的卒中发生率低于普通盐:平均随访4.74年,每1000人年29.14次对33.65次(率比0.86,95%置信区间0.77至0.96;P=0.006)。死亡也更低(率比0.88),严重高钾血症事件没有显著增多,但试验为开放标签设计,且在中国农村开展。

The New England Journal of Medicine

重点论文精讲阅读论文 →
·测量验证研究/综述

智能手表脉搏不规则提醒较少见,做贴片检查者34%确有房颤

在419,297名没有已知心房颤动(房颤)的苹果手表用户中,0.52%收到脉搏不规则提醒;返还可用心电贴片的450人中,34%确认有房颤(97.5%置信区间29至39)。提醒发出时恰有贴片记录的,通知的阳性预测值为0.84(95%置信区间0.76至0.92),但收到提醒者中仅20.8%返还了贴片,没有收到提醒的人未被监测,所以手表没有提醒并不能排除房颤。

The New England Journal of Medicine

重点论文精讲阅读论文 →
心血管健康 →